SCHEDULE: Northstrive Fund II Exits Enveric Biosciences Stake
Beneficial Ownership Exit Filing
Northstrive Fund II LP and Braeden Lichti have filed an amendment to their Schedule 13G, indicating they no longer beneficially own shares of Enveric Biosciences, Inc. as of December 9, 2025.
Summary
- Northstrive Fund II LP and Braeden Lichti, collectively referred to as the Reporting Persons, have filed an Amendment No. 1 to their Schedule 13G.
- This amendment serves as a final amendment and an exit filing, confirming that the Reporting Persons are no longer beneficial owners of any shares of Common Stock of Enveric Biosciences, Inc.
- As of December 9, 2025, both Northstrive Fund II LP and Braeden Lichti hold 0% beneficial ownership in Enveric Biosciences, Inc.
- The original Schedule 13G was filed on December 5, 2025.
- Braeden Lichti is the Manager of Northstrive Fund II LP.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of an institutional investor exiting its beneficial ownership in Enveric Biosciences, Inc. It does not contain information that would inherently suggest a positive or negative outlook for the company itself.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Enveric Biosciences, Inc.'s future performance or strategic direction.
Industry Context
This filing represents a routine disclosure of an institutional investor's divestment of its stake in a publicly traded company. It does not provide insights into broader industry trends or competitive landscape, but rather reflects a specific portfolio decision by Northstrive Fund II LP.
Stakeholder Impact
- Shareholders: May note the divestment of an institutional investor, which could be interpreted in various ways depending on market sentiment and the investor's prior reputation.
- Company Management: The company's management would be aware of the change in its shareholder base, though this filing does not indicate any direct operational impact.
Key Dates
| Date | Description |
|---|---|
| 12/05/2025 | Original Schedule 13G filed with the U.S. Securities and Exchange Commission. |
| 12/09/2025 | Date of event requiring filing, when Reporting Persons ceased to be beneficial owners of Enveric Biosciences, Inc. Common Stock. |
| 12/10/2025 | Date of filing for Amendment No. 1 to Schedule 13G. |
Keywords
Enveric Biosciences, Northstrive Fund II LP, Braeden Lichti, Schedule 13G, Beneficial Ownership, Exit Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.